drugset / Trial / NCT02044627

Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002

NCT02044627

Phase 1 Completed 6 enrolled Esperion Therapeutics, Inc.
NaSingle-groupOpen-labelDiagnostic

Summary

This Phase 1 study will assess the mass balance recover of carbon-14 (14C) labelled ETC-1002 and the routes and rates of excretion of \[14C\]-ETC-1002

Timeline

Start
2013-12
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bempedoic acid Small molecule

Indications